Solid Biosciences $143.75 million follow-on equity offering
Davis Polk advised the joint book-running managers in connection with the $143.75 million public offering of common stock of Solid Biosciences Inc. The common stock is listed on the Nasdaq Global Select Market under the symbol “SLDB.”
Solid Biosciences Inc. is a life sciences company focused on advancing transformative treatments to improve the lives of patients living with Duchenne. Disease-focused and founded by a family directly impacted by Duchenne, Solid Bioscience Inc.’s mandate is simple yet comprehensive – work to address the disease at its core by correcting the underlying mutation that causes Duchenne with its lead gene therapy candidate, SGT-001.
The Davis Polk capital markets team included partners Deanna L. Kirkpatrick and Yasin Keshvargar and associates Jeannette Safi and Ben Somogyi. The tax team included partner Michael Farber and associate Ben Levenback. Partner David R. Bauer and associate Jay Frankel provided intellectual property advice. All members of the Davis Polk team are based in the New York office.